Search | IOVS | ARVO Journals

View

Showing 1 – 13 of 13

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract September 2016

Epiretinal membrane formation following treatment of retinal breaks

Abdallah Jeroudi; Kevin J Blinder

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):4057. doi:

ARVO Annual Meeting Abstract March 2012

The Willingness to Pay for the Prevention of Visual Impairment Among Community Members

Steven M. Kymes; Colleen M. Peters; Aimee I. James; Irwin Tran; Rajendra S. Apte; Kevin J. Blinder; Gaurav K. Shah; Jamie Kambarian; Adam Turpcu; Shoshana Colman

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):1424. doi:

ARVO Annual Meeting Abstract March 2012

The Impact of Diabetic Macular Edema on the Daily Lives of Diabetic Adults---A Qualitative Study

Colleen M. Peters; Aimee I. James; Irwin Tran; Jamie Kambarian; Shoshana Colman; Rajendra S. Apte; Kevin J. Blinder; Guarav K. Shah; Steven M. Kymes

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):5449. doi:

ARVO Annual Meeting Abstract March 2012

Triamcinolone-Assisted Internal Limiting Membrane Peeling During Primary Rhegmatogenous Retinal Detachment Repair Reduces Postoperative Macular Pucker Formation

Rajesh C. Rao; Kevin J. Blinder; Gaurav K. Shah

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):5791. doi:

ARVO Annual Meeting Abstract April 2011

Frequent Monitoring Following Treatment With Dexamethasone Intravitreal Implant

Bryan M. Kim; Jonathan Jonisch; Kevin J. Blinder; Gaurav K. Shah

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):4505. doi:

ARVO Annual Meeting Abstract April 2010

Subretinal Tissue Plasminogen Activator and Bevacizumab for Large Subretinal Hemorrhage From Neovascular Age-Related Macular Degeneration

R. Rajagopal; J. Davies; G. K. Shah; K. J. Blinder

Invest. Ophthalmol. Vis. Sci.. 2010; 51(13):922. doi:

ARVO Annual Meeting Abstract April 2010

Complications of Retinal Detachment Surgery Using Scleral Buckles

K. R. Sivaraman; J. Jonisch; K. J. Blinder; G. K. Shah

Invest. Ophthalmol. Vis. Sci.. 2010; 51(13):6066. doi:

ARVO Annual Meeting Abstract May 2008

Limited Intravitreal Bevacizumab in the Treatment of Choroidal Neovascular Membranes

A. Almony; G. K. Shah; K. J. Blinder

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):296. doi:

ARVO Annual Meeting Abstract May 2008

Intravitreal Bevacizumab for the Treatment of Refractory Diabetic Macular Edema

S. Mehta; K. J. Blinder; G. K. Shah; S. Kymes

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):3488. doi:

ARVO Annual Meeting Abstract May 2008

Safety and Outcomes of 25-Gauge Transconjunctival Vitreoretinal Surgery

R. R. Rathod; R. S. Apte; K. J. Blinder

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):6002. doi:

ARVO Annual Meeting Abstract May 2007

Long-term Efficacy of Photodynamic Therapy With Verteporfin for Choroidal Neovascularization Secondary to Ocular Histoplasmosis Syndrome

P. N. Dayani; G. K. Shah; A. Tewari; K. J. Blinder; H. Hollands; S. Sharma

Invest. Ophthalmol. Vis. Sci.. 2007; 48(13):1435. doi:

ARVO Annual Meeting Abstract May 2007

Intravitreal Bevacizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome

R. Schadlu; A. Sheybana; G. K. Shah; K. J. Blinder

Invest. Ophthalmol. Vis. Sci.. 2007; 48(13):1458. doi:

ARVO Annual Meeting Abstract May 2007

Combined Intravitreal Bevacizumab and Photodynamic Therapy With Verteporfin for Choroidal Neovascularization in Age Related Macular Degeneration

M. S. Dhalla; G. K. Shah; K. J. Blinder; E. H. Ryan, Jr.; R. A. Mittra; A. Tewari

Invest. Ophthalmol. Vis. Sci.. 2007; 48(13):3389. doi:

Advertisement